Abstract 1522
Background
Cancer associated fibroblasts (CAFs) can help tumours evade immune-surveillance by affecting the immune cell infiltrate, mainly via secretion of cytokines and chemokines. CAFs phenotype and spatial relationship to cancer cells alter the kind of cytokines and chemokines they secrete. In Squamous cell carcinoma (SCC), cancer-associated fibroblasts can trigger a Type I Interferon when in direct cell-cell contact with cancer cells.
Methods
Bioinformatics: we used publicly available RNAseq data from The Cancer Genome Atlas (TCGA) for Head and Neck Squamous Cell Carcinoma (HNSCC 518 tumours. [http://firebrowse.org/]) . Using the RSEM normalized gene expression, we divided tumours according to the expression of CAF markers not expressed in cancer cells (FAP, Thy-1, s100a4and PDGFRb). We used CIBERSORT to estimate the abundance of immune cells in the tumours. In vitro assays: we used A431 (human SCC cell line) and CAFs extracted from a human tumour in our lab. We cultured them in either direct cell-to-cell contact or using a transwell. We treated the A431 with AZD6738 (ATR inhibitor), 5-aza-2′-deoxycytidine and cisplatin. We analysed mRNA expression of different interferon response genes by qRT-PCR.
Results
To explore the relevance of CAF influence in the immune infiltrate we analysed RNA seq data from HNSCC in TCGA. Tumours with higher expression of FAP and PDGFRb showed a higher proportion of infiltrating M0 and M2 macrophages. Tumours with lower expression of FAP and PDGFRb had higher proportions of activated dendritic cells and CD8 positive lymphocytes. In an “in vitro” human SCC model, heterotypic cancer cell-CAF contact leads to transfer of double stranded DNA from the cancer cell to the fibroblasts. This interaction triggers cGAS-STING mediated production of Interferon b (IFNb) in the CAFs. We treated cancer cells with drugs that generate genomic damage i.e. AZD6738, 5-aza and cisplatin. Treatment with these drugs increased the signal initiated by IFNb.
Conclusions
CAF subtypes abundance correlates with an immunosuppressive tumour microenvironment in HNSCC. Drugs currently used for routine treatment or in clinical trials for HNSCC modulate cytokine and chemokine production by CAFs in an “in vitro” model.
Clinical trial identification
Legal entity responsible for the study
The Francis Crick Institute.
Funding
Cancer Research UK.
Editorial Acknowledgement
Disclosure
K. Harrington: Consultancy (Includes expert testimony): Amgen, AstraZeneca, BMS, Merck, MSD, Pfizer; Research funding: AstraZeneca, MSD; Honoraria: Amgen, AstraZeneca, BMS, Merck, MSD, Pfizer, Replimune; Speakers' bureau: Amgen, AstraZeneca, BMS, Merck, MSD, Pfizer; Membership on any entity’s Board of Directors or advisory committees: Amgen, AstraZeneca, BMS, Merck, MSD, Pfizer, Replimune (Scientific advisory board memberships). All other authors have declared no conflicts of interest.
Resources from the same session
3816 - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma
Presenter: Nan Shen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5242 - Novel genomic classifier for early stage colorectal cancer patients
Presenter: Elisabeth Letellier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5404 - Baseline Blood Immune Profiling to Predict Response to antiPD-1 in Patients with Advanced Non-Small Cell Lung Cancer
Presenter: Emanuela Romano
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5462 - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient Mismatch Repair (pMMR) colorectal and endometrial cancers.
Presenter: Justine Cohen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5465 - Immune prognostic index (IPI) and Hyper-Progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in Phase 1 trials (Ph1T): can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?
Presenter: Ignacio Matos Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5742 - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
Presenter: Maria Silvia Cona
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5790 - Effects of concomitant genetic alterations on cancer patient overall survival
Presenter: Yu Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5144 - Circulating Exosomal Integrin _v_5 Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer
Presenter: Dake Chu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5149 - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?
Presenter: Rosalinda Sorrentino
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5673 - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?
Presenter: Michela Terlizzi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract